



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/038,760
Filing Date	January 4, 2002
First Named Inventor	Anthony A. Sauvé
Art Unit	1623
Examiner Name	Traviss C. McIntosh III
Attorney Docket Number	96700/725

Sheet	1	of	4
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
(C)	30	Ashamu et al., "Roles for adenosine ribose hydroxyl groups in cyclic adenosine 5'-diphosphate ribose-mediated Ca ²⁺ release." Biochemistry, 36:9509-9517 (1997).	
(D)	31	Bailey et al., "Cyclic aristeromycin diphosphate ribose: a potent and poorly hydrolysable Ca ²⁺ -mobilising mimic of cyclic adenosine diphosphate ribose. FEBS Lett., 379:227-230 (1996).	
(W)	32	Clapper et al., "Pyridine nucleotide metabolites stimulate calcium release from sea urchin egg microsomes desensitized to inositol trisphosphate." J. Biol. Chem., 262:9561-9568 (1987).	
(u)	33	Fernandez et al., "Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues." J. Biol. Regul. Homeostatic Agents, 12:81-91 (1998).	
(u)	34	Fox et al., "Nucleosides. XII. Direct synthesis of 2'-deoxycytidine and its alpha-anomer." J. Am. Chem. Soc., 83:4066-4070 (1961).	
(u)	35	Handlon and Oppenheimer, "Substituent effect on the pH-independent hydrolysis of 2'-substituted nicotinamide arabinosides." J. Org. Chem., 56:5009-5010 (1991)	
(u)	36	Hara-Yokoyama et al., "Complex gangliosides as cell surface inhibitors for the Ecto-NAD ⁺ glycohydrolase of CD38." Biochemistry, 40:888-895 (2001).	
(u)	37	Howard et al., "Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38." Science, 262:1056-1059 (1993).	
(u)	38	Itoh et al., "Molecular cloning of murine BST-1 having homology with CD38 and aplysia ADP-ribosyl cyclase." Biochem. Biophys. Res. Commun., 203:1309-1317 (1994).	
(u)	39	Jackson and Bell, "Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation." J. Immunol., 144:2811-2815 (1990).	

Examiner Signature		Date Considered	5/26/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/038,760
				Filing Date	January 4, 2002
				First Named Inventor	Anthony A. Sauvé
				Art Unit	1623
				Examiner Name	Traviss C. McIntosh III
Sheet	2	of	4	Attorney Docket Number	96700/725

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	40	Jiang et al., "Membrane-permeant esters of phosphatidylinositol 3,4,5-trisphosphate." J. Biol. Chem., 273:11017-11024 (1998).	
	41	Kaisho et al., "BST-1, a surface molecule of bone marrow stromal cell lines that facilitates pre-B-cell growth." Proc. Natl. Acad. Sci. USA, 91:5325-5329 (1994).	
	42	Kang et al., "Synthesis and biological activity of bis(pivaloyloxymethyl) ester of 2'-azido-2'-deoxyuridine 5'-monophosphate." Nucleosides & Nucleotides, 17:1089-1098 (1998).	
	43	Kato et al., "Regulatory role of CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in insulin secretion by glucose in pancreatic beta-cells." J. Biol. Chem., 270:30045-30050 (1995).	
	44	Khoo and Chang, "Localization of plasma membrane CD38 is domain specific in rat hepatocyte." Arch. Biochem. Biophys., 373:35-43 (2000).	
	45	Kruppa et al., "Bioactivatable derivatives of 8-substituted cAMP-analogues." Bioorg. Med. Chem. Lett., 7:945-948 (1997).	
	46	Lee and Aarhus, "ADP-ribosyl cyclase: an enzyme that cyclizes NAD ⁺ into a calcium-mobilizing metabolite." Cell Regul., 2:203-209 (1991).	
	47	Lee and Aarhus, "Fluorescent analogs of NAADP with calcium mobilizing activity." Biochem. Biophys. Acta., 1425:263-271 (1998).	
	48	Li et al., "Membrane-permeant esters of inositol polyphosphates, chemical syntheses and biological applications." Tetrahedron, 53:12017-12040 (1997).	
	49	Mizuguchi et al., "Neuronal localization of CD38 antigen in the human brain." Brain Res., 697:235-240 (1995).	

Examiner Signature		Date Considered	5/26/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete If Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	4	Application Number	10/038,760
				Filing Date	January 4, 2002
				First Named Inventor	Anthony A. Sauvé
				Art Unit	1623
				Examiner Name	Traviss C. McIntosh III
				Attorney Docket Number	96700/725

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
(u)	50	Munshi et al., "Characterization of the active site of ADP-ribosyl cyclase." J. Biol. Chem., 274:30770-30777 (1999).	
(u)	51	Normark et al., "How neutrophils recognize bacteria and move toward infection." Nat. Med., 7:1182-1184 (2001).	
(u)	52	Oppenheimer and Handlon, "Mechanism of NAD-dependent enzymes." In The Enzyme, Sigman, D.L. Ed., Academic Press Inc.: San Diego CA, Chapter 10, 20:453-505 (1992).	
(u)	53	Partida-Sanchez et al., "Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo." Nat. Med., 7:1209-1216 (2001).	
(u)	54	Rusinko and Lee, "Widespread occurrence in animal tissues of an enzyme catalyzing the conversion of NAD ⁺ into a cyclic metabolite with intracellular Ca ²⁺ -mobilizing activity." J. Biol. Chem., 264:11725-11731 (1989).	
(u)	55	Sato et al., "Inhibitor peptide SNP-1 binds to a soluble form of BST-1/CD157 at a 2:2 stoichiometry." Eur. J. Biochem. 264:439-445 (1999).	
(u)	56	Sato et al., "Novel peptide inhibitor of ecto-ADP-ribosyl cyclase of bone marrow stromal cell antigen-1 (BST-1/CD157)." Biochem. J., 337:491-496 (1999).	
(u)	57	Sethi et al., 7-Deaza-8-bromo-cyclic ADP-ribose, the first membrane-permeant, hydrolysis-resistant cyclic ADP-ribose antagonist." J. Biol. Chem., 272:16358-16363 (1997).	
(u)	58	Sleath et al., "Pyridine coenzyme analogues. 3. Synthesis of three NAD ⁺ analogues containing a 2'-deoxy-2'-substituted nicotinamide arabinofuranosyl moiety." J. Org. Chem. 56:3608-3613 (1991).	
(u)	59	States et al., "Similarities in amino acid sequences of alysia ADP-ribosyl cyclase and human lymphocyte antigen CD38." Trends Biochem. Sci., 17:495-496 (1992).	

Examiner Signature		Date Considered	5/26/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/038,760
Filing Date	January 4, 2002
First Named Inventor	Anthony A. Sauvé
Art Unit	1623
Examiner Name	Traviss C. McIntosh III
Attorney Docket Number	96700/725

Sheet 4 of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
W	60	Sun et al., "CD38/ADP-ribosyl cyclase: a new role in the regulation of osteoclastic bone resorption." Cell. Biol., 146:1161-1171 (1999).	
W	61	Wall et al., "Inhibition of the intrinsic NAD ⁺ glycohydrolase activity of CD38 by carbocyclic NAD analogues." Biochem. J., 335:631-636 (1998).	
W	62	Walseth and Lee, "Synthesis and characterization of antagonists of cyclic-ADP-ribose-induced Ca ²⁺ release." Biochem. Biophys. Acta., 1178:235-242 (1993).	
W	63	Walseth et al., "Identification of cyclic ADP-ribose-binding proteins by photoaffinity labeling." J. Biol. Chem., 268:26686-26691 (1993).	
W	64	Wong et al., "Cyclic 3-deaza-adenosine diphosphoribose: a potent and stable analog of cyclic ADP-ribose." Biochem. Biophys. Acta, 1472:555-564 (1999).	
W	65	Wu et al., "Absciscic acid signaling through cyclic ADP-ribose in plants." Science, 278:2126-2130 (1997).	
W	66	Yamamoto-Katayama et al., "Crystallographic studies on human BST-1/CD157 with ADP-ribosyl cyclase and NAD glycohydrolase activities." J. Mol. Biol., 316:711-723 (2002).	

Examiner Signature		Date Considered	5/26/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.